L. Doorn

发表

A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.

M. D. de Jonge, M. Forster, T. Busman, 2021, Future oncology.

Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.

R. Mathijssen, A. Huitema, N. Steeghs, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?

J. Versmissen, R. Mathijssen, A. Danser, 2021, Clinical science.

Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial

R. Mathijssen, S. Bins, F. Eskens, 2021, Clinical pharmacology and therapeutics.

72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors

J. Verweij, H. Gelderblom, P. Rajagopalan, 2006 .

Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance

A. Gibson, A. Sparreboom, Shuiying Hu, 2013, Clinical pharmacology and therapeutics.

Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial

I. B. Borel Rinkes, C. Punt, M. D'Angelica, 2019, BMC Cancer.

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

J. Verweij, E. de Vries, J. Gietema, 2007, British Journal of Cancer.

Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage

R. Touyz, J. Versmissen, H. Baelde, 2022, Clinical science.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

J. Verweij, C. Lamers, M. D. de Jonge, 2009, European Journal of Cancer.

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study

A. Gaast, E. Meerten, L. Doorn, 2007, British Journal of Cancer.

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

V. Diéras, A. van der Gaast, H. Fontaine, 2014, British Journal of Cancer.

Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.

V. Diéras, H. Fontaine, D. Tosi, 2010 .